An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 23 Sep 2019 Interim results assessing treatment of chemotherapy-Induced thrombocytopenia with romiplostim published in the Journal of Clinical Oncology
- 29 May 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 29 May 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.